VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) Files An 8-K Results of Operations and Financial Condition

Item2.02.

On January9, 2017, Vanda Pharmaceuticals Inc. (Vanda) issued a
press release reporting preliminary fourth quarter and full year
2016 results and 2017 financial guidance (the Press Release). The
sections titled Preliminary Fourth Quarter 2016 Results and
Preliminary Full Year 2016 Results of the Press Release are
furnished as Exhibit 99.1 to this Current Report on Form 8-K and
are incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form8-K
and the sections of the Press Release attached hereto titled
Preliminary Fourth Quarter 2016 Results and Preliminary Full Year
2016 Results shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
nor shall they be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended (the Securities
Act), or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

The Press Release also includes information regarding financial
guidance for the year ending December31, 2017 in the section
titled 2017 Financial Guidance of the Press Release.

The information in Item 7.01 of this Current Report on Form8-K
and the section of the Press Release attached hereto titled 2017
Financial Guidance shall not be deemed filed for purposes of
Section18 of the Exchange Act, or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.

About VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.

VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) Recent Trading Information

VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) closed its last trading session down -0.40 at 14.95 with 375,847 shares trading hands.